Humacyte terminates Revenue Interest Purchase Agreement; pays $38M cash + 5.7M shares to purchasers

Humacyte, Inc.

Terminated Revenue Interest Purchase Agreement and Option Agreement with TPC Investments LP and Hook SA LLC as of Dec 15, 2025.
Consideration: $38 million cash (funded via new credit facility) plus 5,725,190 shares of common stock in a registered direct offering.
Offering closes Dec 15, 2025; shares issued under effective shelf registration statement (File No. 333-290231).
Company expects to fund $38M cash payment from proceeds of a new credit facility.
Satisfaction of all obligations under terminated agreements.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Humacyte, Inc. terminated Revenue Interest Purchase Agreement with TPC Investments III LP and TPC Investments Solutions LP valued at $38 million cash and 5,725,190 shares of common stock (effective 2025-12-15).

Action: termination
Counterparty: TPC Investments III LP and TPC Investments Solutions LP
Value: $38 million cash and 5,725,190 shares of common stock
Effective: 2025-12-15

Exact text from the filing

On December 15, 2025, the Humacyte, Inc. (the “Company”) and Humacyte Global, Inc. (“Global”) agreed with TPC Investments III LP and TPC Investments Solutions LP (collectively, the “Purchasers”), and Hook SA LLC, as agent for the Purchasers (the “Purchasers’ Agent”), to terminate the Revenue Interest Purchase Agreement, dated as of May 12, 2023, as amended (the “Purchase Agreement”), by and among the Company, Global, the Purchasers and the Purchasers’ Agent.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-120915

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.